glp-1 receptor agonist structure Peptide sequences and molecular structures of FDA approved RAs Current Insights, Advantages and Challenges
Description
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion

Williams, E

Influence of common medications on diabetic macular edema in type 2 diabetes mellitus

Both drugs activate the same GLP-1 and GIP receptors, so combining them would create overlapping and potentially dangerous receptor overstimulation

Recent studies have found that GLP-1 medications may be linked to a decreased risk for certain cancers, including colorectal cancer

Its anti-atherogenic actions include nitric oxide production, inhibition of cell proliferation in vascular smooth muscle cell proliferation, and suppression of inflammatory responses in monocytes, macrophages, and adipocytes
